Share

November 2018; 5 (6) ArticleOpen Access

Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders

Andrea Marcinnò, Fabiana Marnetto, Paola Valentino, Serena Martire, Alessia Balbo, Aurora Drago, Maria Leto, Marco Capobianco, Giancarlo Panzica, Antonio Bertolotto
First published September 14, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000498
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1576

Share

Article Information

vol. 5 no. 6 e498
DOI: 
https://doi.org/10.1212/NXI.0000000000000498
PubMed: 
30258855
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received March 26, 2018
  • Accepted in final form July 20, 2018
  • First Published September 14, 2018.
Copyright & Usage: 
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Andrea Marcinnò, MD*,
    2. Fabiana Marnetto, MSc*,
    3. Paola Valentino, MSc,
    4. Serena Martire, MSc,
    5. Alessia Balbo, MLT,
    6. Aurora Drago, MSc,
    7. Maria Leto, MD,
    8. Marco Capobianco, MD,
    9. Giancarlo Panzica, PhD and
    10. Antonio Bertolotto, MD
  1. Andrea Marcinnò, MD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Mylan, funding for travel to 2017 Italian Neurology Society congress, (2) F. Hoffmann - La Roche, funding for travel to 2017 ECTRIMS-ACTRIMS joint congress

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. (1) MD-PhD Programm, University of Turin

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Fabiana Marnetto, MSc*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Biogen Idec, speaker honoraria 2. Merck Serono, speaker honoraria 3. Euroimmun Italia, travel and speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Fondazione Italiana Sclerosi Multipla, grant n. 2014/R/1.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Paola Valentino, MSc,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)BiogenIdec,speaker honoraria, (2)Merck Serono, speaker honoraria, (3) Novartis, speaker honoraria, (4) Euroimmun, travel grant

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Serena Martire, MSc,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) BiogenIdec, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Alessia Balbo, MLT,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Aurora Drago, MSc,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Maria Leto, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Marco Capobianco, MD,
    9. Scientific Advisory Boards:

    1. Commercial entity: Biogen, Sanofi-Genzyme, Novartis, Bayer-Schering

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaking honoraria from: Almirall, Biogen, Novartis, Sanofi-Genzyme, Teva

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Giancarlo Panzica, PhD and
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Frontiers in Endocrinology - Associate Review Editor Biology of Sex Differences - Member of the Editorial Board Cell and Tissue Research - Member of the Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. - University of Torino, Local Research Grants (no number) for year 2016-17-18

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Antonio Bertolotto, MD
    11. Scientific Advisory Boards:

    1. (1)Almirall,(2)Bayer,(3)BiogenIdec, (4)Genzyme with approval by the Director of AOU San Luigi University Hospital

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)BiogenIdec, (2)Genzyme, (3)Novartis, (4)Sanofi- Aventis, (5)Teva

    Editorial Boards:

    1. (1)?Multiple Sclerosis International?, editorial Board, since 2012, (2)?Progress in Neuroscience?, editorial board, since 2012, (3)?Dataset Papers in Neuroscience?, editorial board, since 2012, (4)?Journal of Multiple Sclerosis?, editorial board, since 2014, (5)?Neurology and Therapy?, editorial board, since 2014, (6)?Multiple Sclerosis and demyelinating disorders?, editorial board, since 2015.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1)Merck Serono Italy, (2)Biogen, (3)Euroimmun

    Research Support, Government Entities:

    1. 1)Italian Ministry of Health,RF-2013-02357497,principal investigator, 2016-2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1)Italian Multiple Sclerosis Foundation(FISM), 2014/PMS/1, (2)Italian Multiple Sclerosis Foundation(FISM, 2015/R/05,(3)Ricerca Biomedica ONLUS Foundation(FORB),(4)San Luigi ONLUS.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Neuroscience Institute Cavalieri Ottolenghi (NICO) (A.M., P.V., S.M., A. Balbo, A. Bertolotto, F.M., G.P.), Orbassano, Turin, Italy; Neurologia–CRESM (A.M., P.V., S.M., A. Balbo, A. Bertolotto, F.M., M.C.), AOU San Luigi Gonzaga, Orbassano, Turin, Italy; “Rita Levi Montalcini” Neuroscience Department (F.M., G.P.), University of Turin, TO, Italy; and Humanitas Hospital Gradenigo (A.D., M.L.), Turin, Italy.
  1. Correspondence
    Fabiana Marnetto fabiana.marnetto{at}gmail.com
View Full Text

Article usage

Article usage: September 2018 to August 2023

AbstractFullPdfSource
Sep 2018029456Highwire
Oct 2018048263Highwire
Nov 2018028777Highwire
Dec 2018017658Highwire
Jan 2019427923Highwire
Feb 20191119229Highwire
Mar 2019511121Highwire
Apr 20191212727Highwire
May 2019611726Highwire
Jun 20191112331Highwire
Jul 201999927Highwire
Aug 201949812Highwire
Sep 2019212126Highwire
Oct 20191011220Highwire
Nov 2019626034Highwire
Dec 201968722Highwire
Jan 202069932Highwire
Feb 202018719Highwire
Mar 202019419Highwire
Apr 2020411436Highwire
May 20201311425Highwire
Jun 2020611538Highwire
Jul 2020168032Highwire
Aug 202069512Highwire
Sep 2020413124Highwire
Oct 20201011319Highwire
Nov 2020117435Highwire
Dec 2020107326Highwire
Jan 202187833Highwire
Feb 202136518Highwire
Mar 202155716Highwire
Apr 202156418Highwire
May 202157211Highwire
Jun 202145625Highwire
Jul 202156829Highwire
Aug 202126820Highwire
Sep 20211510027Highwire
Oct 2021148943Highwire
Nov 202167431Highwire
Dec 202186911Highwire
Jan 202214912Highwire
Feb 202266916Highwire
Mar 20221310421Highwire
Apr 202294022Highwire
May 202266120Highwire
Jun 202258427Highwire
Jul 202296321Highwire
Aug 2022923818Highwire
Sep 2022720128Highwire
Oct 2022128720Highwire
Nov 20221824347Highwire
Dec 202236112Highwire
Jan 202358118Highwire
Feb 202356621Highwire
Mar 202368515Highwire
Apr 202383824Highwire
May 2023916524Highwire
Jun 2023210914Highwire
Jul 202335426Highwire
Aug 202356119Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles